IsoRay, Inc. (NYSEAMERICAN:ISR) VP Michael Krachon bought 55,000 shares of the business’s stock in a transaction that occurred on Monday, November 20th. The shares were acquired at an average cost of $0.50 per share, with a total value of $27,500.00. Following the completion of the purchase, the vice president now owns 19,609 shares of the company’s stock, valued at $9,804.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

IsoRay, Inc. (NYSEAMERICAN ISR) traded up $0.02 during midday trading on Tuesday, reaching $0.48. 113,800 shares of the company’s stock traded hands, compared to its average volume of 113,058. IsoRay, Inc. has a 52 week low of $0.38 and a 52 week high of $0.70.

IsoRay (NYSEAMERICAN:ISR) last released its quarterly earnings data on Tuesday, November 14th. The healthcare company reported ($0.03) EPS for the quarter. The business had revenue of $1.21 million for the quarter. IsoRay had a negative return on equity of 65.23% and a negative net margin of 135.40%.

TRADEMARK VIOLATION WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at

Separately, Maxim Group set a $3.00 price target on shares of IsoRay and gave the stock a “buy” rating in a research note on Wednesday, November 15th.

IsoRay Company Profile

IsoRay, Inc is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds.

Receive News & Ratings for IsoRay Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay Inc. and related companies with's FREE daily email newsletter.